HK-listed gold stocks jump as US economic fears boost bullion prices
Investing.com - Passage Bio reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Passage Bio announced earnings per share of $-0.49 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.78 on revenue of $0.
Passage Bio 's are down 4.96% and is trading at $1.34 , still down 84.96% from its 52 week high of $8.91 set on Wednesday, November 10, 2021.
Passage Bio shares gained 11.67% to trade at $1.34 in intra-day trade the report.
Passage Bio follows other major Healthcare sector earnings this month
Passage Bio's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar